- Home
- BOLD vs VTGN Comparison
BOLD vs VTGN Comparison
Compare BOLD & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | VTGN |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 28.8M |
| IPO Year | 2024 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BOLD | VTGN |
|---|---|---|
| Price | $1.16 | $0.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $4.00 | $0.90 |
| AVG Volume (30 Days) | 144.9K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $93.93 |
| Revenue Next Year | N/A | $243.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $0.43 |
| 52 Week High | $2.05 | $5.14 |
Technical Indicators
Market Signals| Indicator | BOLD | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 37.98 |
| Support Level | $1.10 | $0.43 |
| Resistance Level | $1.17 | $0.58 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 91.62 | 93.19 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.